The European Medicines Agency decided to review the safety of iron medications administered directly into the vein. This decision came after serious cases of low blood phosphate and bone problems were identified in patients who had received only one or two doses of these medications.
The medications in question are used by thousands of patients in Portugal. The review is being carried out by the Pharmacovigilance Risk Assessment Committee, which will analyze all available data on this class of medications.
Healthcare professionals and patients should be aware of the symptoms associated with these adverse reactions. The ongoing analysis aims to determine whether new safety measures are needed to protect patients using these treatments.
This Infarmed alert comes in the context of a broader European assessment of the risks of these intravenously administered medications.
